FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics. Described is drug form of combined compositions of growth hormone (GH) and insulin-like growth factor (IGF-1). Composition includes aggregation-preventing substance, histidine or citrate buffer, non-ionic surface-active substance, and optionally contains preservative, tonicity modifier or filler. As aggregation-preventing substance arginine is used, with sodium chloride being used as tonicity modifier. Method of composition obtaining is also disclosed.
EFFECT: invention provides stable transparent pharmaceutical compositions without formation of aggregates.
18 cl, 2 dwg, 14 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION COMPRISING GROWTH HORMONE, AMINO ACID AND NON-IONIC DETERGENT | 1997 |
|
RU2236250C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2773747C2 |
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
| ANTIBODY CONTAINING PREPARATION | 2017 |
|
RU2748046C2 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
| PHARMACEUTICAL FORMULA CONTAINING HUMAN ANTI-TSLP ANTIBODY | 2016 |
|
RU2794148C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| LIQUID COMPOSITION OF HUMAN GROWTH HORMONE WITH PROLONGED ACTION | 2011 |
|
RU2623026C2 |
